These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 36814929)
1. Construction and validation of a cuproptosis-related prognostic model for glioblastoma. Zhang B; Xie L; Liu J; Liu A; He M Front Immunol; 2023; 14():1082974. PubMed ID: 36814929 [TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
3. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma. Dai L; Zhou P; Lyu L; Jiang S BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959 [TBL] [Abstract][Full Text] [Related]
4. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
5. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma. Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X Front Oncol; 2023; 13():1152681. PubMed ID: 37333810 [TBL] [Abstract][Full Text] [Related]
6. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma. Zhang Y; Zhou J; Li H; Liu Y; Li J BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925 [TBL] [Abstract][Full Text] [Related]
7. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma. Wang L; Yao B; Yang J; Tian Z; He J BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684 [TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
9. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
10. Targeting copper death genotyping associated gene RARRES2 suppresses glioblastoma progression and macrophages infiltration. Yan T; Yang H; Meng Y; Li H; Jiang Q; Liu J; Xu C; Xue Y; Xu J; Song Y; Chu X; Wang L; Chen X; Che F Cancer Cell Int; 2023 May; 23(1):105. PubMed ID: 37246211 [TBL] [Abstract][Full Text] [Related]
11. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
12. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R Front Immunol; 2022; 13():990790. PubMed ID: 36248822 [TBL] [Abstract][Full Text] [Related]
13. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA. Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P Front Immunol; 2022; 13():919231. PubMed ID: 35967366 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J Front Genet; 2023; 14():1094793. PubMed ID: 36891150 [No Abstract] [Full Text] [Related]
15. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma. Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423 [TBL] [Abstract][Full Text] [Related]
16. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma. Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C Front Genet; 2023; 14():1124439. PubMed ID: 36936439 [No Abstract] [Full Text] [Related]
17. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma. Yang BF; Ma Q; Hui Y; Gao XC; Ma DY; Li JX; Pei ZX; Huang BR Transl Cancer Res; 2023 Dec; 12(12):3327-3345. PubMed ID: 38192999 [TBL] [Abstract][Full Text] [Related]
18. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
19. The role of cuproptosis-related gene in the classification and prognosis of melanoma. Liu JY; Liu LP; Li Z; Luo YW; Liang F Front Immunol; 2022; 13():986214. PubMed ID: 36341437 [TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer. Huang Y; Yin D; Wu L Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]